The  effects of pharmacist interventions on health outcomes in patients with advanced prostate cancer in Brazil

Patricia Melo Aguiar; Ana Luiza Pereira Mori; Maria GF de Lima; Magali Rossi; Maria Aparecida Nicoletti; Karina Fatel; Ana Lúcia Lopes; Teresa Coan; Oscar Fujita; Sílvia  Storpirtis

doi:10.1590/s2175-97902021000219273

Authors

Patricia Melo Aguiar School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil https://orcid.org/0000-0002-3957-4533
Ana Luiza Pereira Mori School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
Maria GF de Lima School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
Magali Rossi School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
Maria Aparecida Nicoletti School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil
Karina Fatel Secretariat of Health of the State of Sao Paulo, São Paulo, Brazil
Ana Lúcia Lopes Teaching Hospital of University of São Paulo, São Paulo, Brazil
Teresa Coan Teaching Hospital of University of São Paulo, São Paulo, Brazil
Oscar Fujita Teaching Hospital of University of São Paulo, São Paulo, Brazil
Sílvia Storpirtis School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil

DOI:

https://doi.org/10.1590/s2175-97902021000219273

Keywords:

Pharmacist, Pharmaceutical care, Prostate cancer, Adverse drug reaction

Abstract

This study examined the effects of pharmacist interventions for patients with advanced prostate cancer. A pre-post study was conducted between October 2014 and August 2017 in a community pharmacy in Brazil for outpatients with advanced prostate cancer, aged ≥ 18 years, using cyproterone acetate and/or goserelin. The patients had face-to-face meetings with a pharmacist who dispensed antiandrogenic drugs and performed interventions aimed at solving and/or preventing drug-therapy problems. Primary outcomes regarding prostate-specific antigen (PSA) and testosterone levels were compared at 0, 6, and 12 months, whereas secondary outcomes-medication adherence and quality of life-were compared at baseline and at the 12-month follow-up. Medication adherence was assessed using the Morisky-Green test, and quality of life was measured by the Medical Outcomes Study 36-item Short Form (SF-36) and the Functional Assessment of Cancer Therapy-Prostate (FACT-P). The analysis included 20 patients; 311 drug-therapy problems were identified and most of them were related to adverse reactions (78.5%). The most common adverse reactions were reduced libido, erectile dysfunction, hyperglycemia, fatigue, and gynecomastia. Testosterone levels significantly decreased at 6 months, and PSA levels at 6 and 12 months. No significant changes in adherence were noted at the end of the study. A significant increase in the “pain” domain and an improvement trend in the “physical aspects” and “vitality” domains were observed based on the SF-36 instrument. The findings show that pharmacist interventions were able to improve PSA and testosterone levels, and some domains of quality of life of patients.

Downloads

Download data is not yet available.

References

Aguiar PM, Balisa-Rocha BJ, Brito GC, Lyra Junior DP. Pharmaceutical care program for elderly patients with uncontrolled hypertension. J Am Pharm Assoc. 2012;52: 515-518.

Bellardita L, Donegani S, Spatuzzi AL, Valdagni R. Multidisciplinary Versus One-on-One Setting: A Qualitative Study of Clinicians’ Perceptions of Their Relationship With Patients With Prostate Cancer. J Oncol Pract. 2011;7(1): e1-e5.

Borras JM, Albreht T, Audisio R, Briers E, Casali P, Esperou H, et al. Policy statement on multidisciplinary cancer care. Eur J Cancer. 2014;50(3):475-80.

Brasil. Lei 8080 de 19 de setembro de 1990. Dispõe sobre as condições para a promoção, proteção e recuperação da saúde, a organização e o funcionamento dos serviços correspondentes e dá outras providências. Diário Oficial da União 1990; set 20.

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Caderno 3: Planejamento e Implantação de Serviços de Cuidados Farmacêuticos na Atenção Básica à Saúde: A Experiência de Curitiba. Cuidado Farmacêutico na Atenção Básica / Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos. -1. Ed. rev. - Brasília: Ministério da Saúde, 2015a. 120p.

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência Farmacêutica e Insumos Estratégicos. Caderno 2: Capacitação para Implantação dos Serviços de Clínica Farmacêutica. Cuidado Farmacêutico na Atenção Básica / Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos. -1. Ed. rev. - Brasília: Ministério da Saúde, 2015b. 304p.

Ciconelli RM, Ferraz MB, Santos WS, Meinã EOI, Quaresma MR. Translation to Portuguese and validation of the generic questionnaire for assessing quality of life SF-36 (SF-36 Brazil). Rev. Bras. J. Rheumatol. 1999;39:143-50.

Chieffi AL, Barata RB. Ações judiciais: estratégia da indústria farmacêutica para introdução de novos medicamentos. Rev. Saúde Pública. 2010;44(3):421-429.

Colombo LRP, Aguiar PM, Lima TM, Storpirtis S. The effects of pharmacist interventions on adult outpatients with cancer: a systematic review. J Clin Pharm Ther. 2017; 42(4):414-24.

Correr CJ, Melchiors AC, Fernandez-Llimos F, Pontarolo R. Effects of a pharmacotherapy follow-up in community pharmacies on type 2 diabetes patients in Brazil. Int J Clin Pharm. 2011;33(2):273-80.

Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016; 375:1425-1437.

Esper P, Mo F, Chodak G, Sinner M, Cella D, Pienta KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology. 1997;50:920-928.

Figueiredo TA, Pepe VLE, Osorio-de-Castro CGS. Um enfoque sanitário sobre a demanda judicial de medicamentos. Physis. [Internet]. 2010;20(1):101-118.

Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524-548.

Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21:54-376.

Kehrer JP, Eberhart G, Wing M, Horon K. Pharmacy’s role in a modern health continuum. Can Pharm J (Ott). 2013;146:321-4.

Kheir NM, Van Mil JWF, Shaw JP, Sheridan JL. Health-related quality of life measurement in pharmaceutical care: Targeting an outcome that matters. Pharm World Sci. 2004;26:125-28.

Liekweg A, Westfeld M, Jaehde U. From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer care. Support Care Cancer. 2004;12(2): 73-9.

Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, et al. Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer . 2012;20(11): 2669-77.

Margarit C, Juliá J, López R, Anton A, Escobar Y, Casas A, et al. Breakthrough cancer pain - still a challenge. J Pain Res. 2012;5:559-66.

Melchiors AC, Correr CJ, Rossignoli P, Pontarolo R, Fernández-Llimós F. Humanistic-outcomes questionnaires in diabetes research and practice. Am J Health-Syst Pharm. 2005;62:354-55.

Milosavljevic A, Aspden T, Harrison J. Community pharmacist-led interventions and their impact on patients’ medication adherence and other health outcomes: a systematic review. Int J Pharm Pract. 2018; 26(5):387-397.

Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a selfreported measure of medication adherence. Med Care. 1986;24(1):67-74.

Mottet N, Bellmunt J, Briers E, Bolla M, Cornford P, De Santis M. Guidelines on Prostate Cancer - European Urological Association. 2016.

Nguyen PL, Alibhai SM, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825-36.

Patel JM, Holle LM, Clement JM, Bunz T, Niemann C, Chamberlin KW. Impact of a pharmacist-led oral chemotherapy-monitoring program in patients with metastatic castrate-resistant prostate cancer. J Oncol Pharm Pract. 2016;22(6):777-783.

Ribed A, Romero-Jiménez RM, Escudero-Vilaplana V, Iglesias-Peinado I, Herranz-Alonso A, Codina C, et al. Pharmaceutical care program for onco-hematologic outpatients: safety, efficiency and patient satisfaction. Int J Clin Pharm . 2016; 38(2):280-8.

Sierra MS, Soerjomataram I, Forman D. Prostate cancer burden in Central and South America. Cancer Epidemiol. 2016;44 Suppl 1:S131-S140.

Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, et al. Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. Crit Rev Oncol Hematol. 2015;95(2):133-43.

Vantard N, Ranchon F, Schwiertz V, Gourc C, Gauthier N, Guedat MG, et al. EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther . 2015;40(2): 196-203.

Wiecek E, Tonin FS, Torres-Robles A, Benrimoj SI, Fernandez-Llimos F, Garcia-Cardenas V. Temporal effectiveness of interventions to improve medication adherence: A network meta-analysis. PLoS One. 2019;14(3):e0213432.

The effects of pharmacist interventions on health outcomes in patients with advanced prostate cancer in Brazil

Authors

DOI:

Keywords:

Abstract

Downloads

References

Downloads

Published

Issue

Section

License

How to Cite

Funding data